In late 2025, the FDA approved an oral semaglutide formulation (Wegovy oral) for weight management at 25mg and 50mg doses, with clinical trials showing 13-14% body weight reduction
This has raised interest in potential applications for Alzheimers disease and other neuro-degenerative conditions
Biomed Rep 4:519522 Honda Y, Kessoku T, Sumida Y, Kobayashi T, Kato T, Ogawa Y, Tomeno W, Imajo K, Fujita K, Yoneda M, Kataoka K, Taguri M, Yamanaka T, Seko Y, Tanaka S, Saito S, Ono M, Oeda S, Eguchi Y, Aoi W, Sato K, Itoh Y, Nakajima A (2017) Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study
The key is returning to your regular day the following weekdo not accelerate your next injection just because this one was early